Alvimopan
Active ingredient: Alvimopan
In short: Alvimopan capsules are indicated to accelerate the time to upper and lower gastrointestinal recovery following surgeries that include partial bowel resection with primary anastomosis.
What is Alvimopan used for?
Alvimopan capsules are indicated to accelerate the time to upper and lower gastrointestinal recovery following surgeries that include partial bowel resection with primary anastomosis.
⚠ Boxed warning (FDA's strongest warning)
There was a greater incidence of myocardial infarction in alvimopan-treated patients compared to placebo-treated patients in a 12-month clinical trial, although a causal relationship has not been established. In short-term trials with alvimopan, no increased risk of myocardial infarction was observed
.
Because of the potential risk of myocardial infarction with long-term use, alvimopan is available only through a restricted program for short-term use (15 doses) under a Risk Evaluation and Mitigation Strategy (REMS) called the Alvimopan REMS Program
.
Alvimopan dosage
For hospital use only. The recommended adult dosage of alvimopan capsules is 12 mg administered 30 minutes to 5 hours prior to surgery followed by 12 mg twice daily beginning the day after surgery until discharge for a maximum of 7 days. Patients should not receive more than 15 doses of alvimopan capsules.
Alvimopan capsules can be taken with or without food
.
How to take Alvimopan — instructions & advice from the label
Recent Use of Opioids:
Inform patients that they must disclose long-term or intermittent opioid pain therapy to their healthcare provider, including any use of opioids in the week prior to receiving alvimopan. Inform patients that recent use of opioids may make them more susceptible to adverse reactions to alvimopan, primarily those limited to the gastrointestinal tract (e.g., abdominal pain, nausea and vomiting, diarrhea).
Hospital Use Only:
Inform patients that alvimopan capsules are available only through a program called the Alvimopan REMS Program under a REMS that restricts use to enrolled hospitals because of the potential risk of myocardial infarction with long-term use of alvimopan. Alvimopan capsules are for hospital use only for no more than 7 days after their bowel resection surgery.
Most Common Adverse Reaction:
Inform patients that the most common adverse reaction with alvimopan in patients undergoing surgeries that include bowel resection is dyspepsia.
Brands listed are the trademarks of their respective owners.
Manufactured by:
Hikma Pharmaceuticals USA Inc.
Marketed by:
GSMS, Incorporated
Camarillo, CA 93012 USA
C50001430/01
Revised January 2024
Warnings & precautions
Do not take this medicine if: Alvimopan capsules are contraindicated in patients who have taken therapeutic doses of opioids for more than 7 consecutive days immediately prior to taking alvimopan capsules
.
There were more reports of myocardial infarctions in patients treated with alvimopan 0.5 mg twice daily compared with placebo-treated patients in a 12-month study of patients treated with opioids for chronic non-cancer pain (alvimopan 0.5 mg, n = 538; placebo, n = 267). In this study, the majority of myocardial infarctions occurred between 1 and 4 months after initiation of treatment. This imbalance has not been observed in other studies of alvimopan in patients treated with opioids for chronic pain, nor in patients treated within the surgical setting, including patients undergoing surgeries that included bowel resection who received alvimopan 12 mg twice daily for up to 7 days (the indicated dose and patient population; alvimopan 12 mg, n = 1,142; placebo, n = 1,120). A causal relationship with alvimopan with long-term use has not been established.
Alvimopan capsules are available only through a program under a REMS that restricts use to enrolled hospitals
.
Alvimopan capsules are available only through a program called the Alvimopan REMS Program that restricts use to enrolled hospitals because of the potential risk of myocardial infarction with long-term use of alvimopan capsules
.
Notable requirements of the Alvimopan REMS Program include the following:
Alvimopan capsules are available only for short-term (15 doses) use in hospitalized patients. Only hospitals that have enrolled in and met all of the requirements for the Alvimopan REMS Program may use alvimopan capsules. …
Alvimopan side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Potential Risk of Myocardial Infarction with Long-Term Use
Gastrointestinal-Related Adverse Reactions in Opioid-Tolerant Patients
Risk of Serious Adverse Reactions in Patients with Severe Hepatic Impairment
Risk of Serious Adverse Reactions in Patients with Complete Gastrointestinal Obstruction
Risk of Serious Adverse Reactions in Pancreatic and Gastric Anastomoses
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be compared directly with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The adverse event information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.
The data described below reflect exposure to alvimopan 12 mg in 1,793 patients in 10 placebo-controlled studies. The population was 19 to 97 years old, 64% were female, and 84% were Caucasian; 64% were undergoing a surgery that included bowel resection. The first dose of alvimopan was administered 30 minutes to 5 hours before the scheduled start of surgery and then twice daily until hospital discharge (or for a maximum of 7 days of postoperative treatment). …
Drug interactions
Coadministration of alvimopan does not appear to alter the pharmacokinetics of morphine and its metabolite, morphine-6-glucuronide, to a clinically significant degree when morphine is administered intravenously. Dosage adjustment for intravenously administered morphine is not necessary when it is coadministered with alvimopan.
A population pharmacokinetic analysis suggests that the pharmacokinetics of alvimopan were not affected by concomitant administration of acid blockers (proton pump inhibitors (PPIs), histamine-2 (H
2) receptor antagonists) or antibiotics. No dosage adjustments are necessary in patients taking acid blockers or antibiotics with alvimopan.
About this medicine
Alvimopan capsules contain alvimopan, an opioid antagonist. Chemically, alvimopan is the single stereoisomer [[2(S)-[[4(
R)-(3-hydroxyphenyl)-3(
R),4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]amino]acetic acid dihydrate. It has the following structural formula:
Alvimopan is a white to light beige powder with a molecular weight of 460.6, and the empirical formula is C
25H
32N
2O
4•2H
2O. It has a solubility of <0.1 mg/mL in water or buffered solutions between pH 3.0 and 9.0, 1 to 5 mg/mL in buffered solutions at pH 1.2, and 10 to 25 mg/mL in aqueous 0.1 N sodium hydroxide. At physiological pH, alvimopan is zwitterionic, a property that contributes to its low solubility.
Alvimopan capsules for oral administration contain 12 mg of alvimopan on an anhydrous basis suspended in the inactive ingredient polyethylene glycol 3350. The capsule shell contains FD&C Blue 1, gelatin, sodium lauryl sulfate, and titanium dioxide. The black ink contains ammonium hydroxide, ferrosoferric oxide, propylene glycol, and shellac. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 10e39d3b-8621-16f8-e063-6294a90a254e. Read the full official label on DailyMed.